Bio-Path Holdings Inc  

(Public, NASDAQ:BPTH)   Watch this stock  
Find more results for BPTH
2.64
+0.13 (5.18%)
May 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.38 - 2.70
52 week 0.99 - 3.19
Open 2.49
Vol / Avg. 188,326.00/307,322.00
Mkt cap 239.84M
P/E     -
Div/yield     -
EPS -0.06
Shares 89.76M
Beta 2.05
Inst. own 12%
May 11, 2016
Q1 2016 Bio Path Holdings Inc Earnings Call - 8:30AM EDT - Add to calendar
May 10, 2016
Q1 2016 Bio Path Holdings Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 16, 2016
Q4 2015 Bio Path Holdings Inc Earnings Release
Mar 15, 2016
Bio Path Holdings Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.19% -41.68%
Return on average equity -55.71% -44.20%
Employees 11 -
CDP Score - -

Address

4710 Bellaire Blvd Ste 210
BELLAIRE, TX 77401-4505
United States - Map
+1-832-7421357 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Bio-Path Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer drugs under a license arrangement. The Company's lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP1001) is undergoing clinical trials. The Company's two liposomal antisense drug candidates are focused to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and follicular lymphoma. BP1001 is its lead liposome delivered antisense drug candidate, which has been clinically tested in patients having AML, CML, MDS and ALL. BP-100-1.02 (Bcl-2 or BP1002) is its second liposome delivered antisense drug candidate. Clinical targets for BP1002 include lymphoma, breast cancer, colon cancer, prostate cancer and leukemia. The Company has a drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense.

Officers and directors

Peter Henry Nielsen Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer
Age: 66
Bio & Compensation  - Reuters
Ulrich W. Mueller Ph.D. Chief Operating Officer, Secretary
Age: 48
Bio & Compensation  - Reuters
Douglas P. Morris Director
Age: 76
Bio & Compensation  - Reuters
Heath W. Cleaver CPA Independent Director
Age: 41
Bio & Compensation  - Reuters
Michael J. Garrison Independent Director
Age: 45
Bio & Compensation  - Reuters
Amy P. Sing M.D. Independent Director
Bio & Compensation  - Reuters